News

The US Patent No 7,704,977, ‘Solid Oral Dosage Form Containing an Enhancer’ covers Orazol tablets, an oral form of zoledronic acid, a bisphosphonate. The expiry date on this

Namenda is a NMDA-receptor antagonist. It works by blocking excess activity of a substance in the brain called glutamate, which may reduce the symptoms associated with Alzheimer disease.

As part of the agreement, Meda is expected to take over full responsibility for development and commercialisation of the compound. Flupirtine is currently in Phase II development for

The increase results from the recognition as revenues during the first quarter of 2010 of EUR7.42m corresponding to the initial license payment received from Bausch + Lomb following

Dynavax Technologies said that this starts a 12-month follow-up on these subjects and sets the study’s completion for May 2011. The event supports its goal of a BLA

Stem and regenerative cells were prepared and made available at the point-of-care using the Celution System, the cell processing device developed by trial sponsor Cytori Therapeutics. Cytori said

The initiation of this study marks the commencement of the Keryx’s Phase 3 registration program for Zerenex, which is being conducted in accordance with a special protocol assessment

Amylin Pharmaceuticals, Eli Lilly and Alkermes have claimed that Bydureon is the proposed brand name for exenatide once weekly. It is an investigational, extended-release medication for type 2

Under the agreed terms Intercell is expected to pay EUR15m to Cytos. Intercell is expected to own certain unpartnered monoclonal antibody assets, including promising pre-clinical anti-infective antibody candidates